二甲双胍对降低2型糖尿病患者阿尔茨海默病发病率的效果分析

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of Metformin on reducing the incidence rate of Alzheimer′s disease(AD)in the patients with type 2 diabetes mellitus.Methods A total of 90 patients with type 2 diabetes mellitus who were admitted to our hospital from January to December in 2017,were selected as the research subjects,and were randomly divided into observation group and control group according to the random number table,45 patients in each group.The observation group were given Metformin,and patients in the control group were given Acarbose Tablets for treatment.The effect of different treatment methods on the therapeutic effect,insulin resistance (HOMA-IR),AD,and incidence rate of adverse reactions were compared between the two groups of patients.Results The observation group was significantly lower than that in the control group in terms of fasting plasma glucose(FBG),2 h postprandial blood glucose(2 h PG),fasting insulin(FINs),glycosylated hemoglobin(HbA1c),peripheral blood leukocyte,body mass index(BMI)(P＜0.05).The blood vitamin B12and connecting peptide(C peptide)were significantly higher than that in the control group(P＜0.05).The observation group was significantly lower than that in the control group in terms of HOMA-IR(P＜0.05).The incidence rate of AD and adverse reactions was significantly lower than that in the control group,the differences were statistically significant(P＜0.05).Conclusion When Metformin is used in the patients with type 2 diabetes,it can not only reduce HOMA-IR and the incidence rate of AD，it can also improve the patient-related indicators,maintain blood sugar stability,and the incidence rate of adverse reactions is less.This method is worthy of application and promotion.

Key words： Type 2 diabetes mellitus Metformin Alzheimer&prime s disease Therapeutic effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XU Xiao-ling

Cite this article:

XU Xiao-ling. Analysis on the effect of Metformin on reducing the incidence rate of Alzheimer′s disease in the patients with type 2 diabetes mellitus[J]. 中国当代医药, 2018, 25(13): 135-137.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I13/135

[1]	邹靖锋，谢珂，郭培燕，等.针刺治疗阿尔茨海默病临床随机对照试验 Meta 分析[J].西部中医药，2016，29（1）：80-84.
[2]	黄隽超，尚兰，张建新，等.阿尔茨海默病患者血清S100B蛋白和抗脑抗体浓度与认知功能关系[J].中国心理卫生杂志，2017，31（7）：523-527.
[4]	雷曦，王健辉，程肖蕊，等.防治阿尔茨海默病多靶点药物研究进展[J].国际药学研究杂志，2016，43（2）：205-215.
[5]	毕丹蕾，文朗，熊伟，等.阿尔茨海默病的可能药物靶点和临床治疗研究进展[J].中国药理学与毒理学杂志，2015，29（4）：507-536.
[6]	唐毅.阿尔茨海默病诊断标准：从临床诊断到病理生理诊断[J].山东大学学报（医学版），2017，55（10）：14-20.
[7]	徐霞.瑞格列奈联合二甲双胍治疗磺脲类降糖药继发失效的 2 型糖尿病 53 例[J].中国药业，2015，24（5）：68-69.
[8]	邵淑玲.瑞格列奈联合二甲双胍治疗2型糖尿病的临床疗效[J].中国老年学杂志，2015，35（12）：3301-3302.
[9]	蒙光义，彭评志，庞家莲，等.利拉鲁肽联合二甲双胍治疗2型糖尿病临床疗效和安全性评估[J].医学综述，2015，21（17）：3223-3226.
[10]	姚璐，田国祥，武云涛，等.二甲双胍分别联合利拉鲁肽及甘精胰岛素治疗2型糖尿病的临床观察[J].中国循证心血管医学杂志，2015，7（1）：100-102.
[11]	李锦华，王娜.沙格列汀联合二甲双胍治疗2型糖尿病临床疗效的系统评价[J].中国老年学杂志，2016，36（5）：1102-1104.
[12]	陈光明，胡艳飞，楼雪勇，等.单用二甲双胍控制不佳的2型糖尿病患者联用沙格列汀或格列美脲的临床研究[J].中国临床药理学杂志，2015，31（19）：85-86.
[13]	王丹彤.西格列汀联合二甲双胍对2型糖尿病胰岛素抵抗及脂联素的影响[J].中国药业，2015，24（16）：54-55.
[14]	万瑾舒，张孟仁.二甲双胍对认知功能影响的研究进展[J].中国糖尿病杂志，2016，24（12）：1140-1143.
[15]	运会喜.阿尔茨海默病治疗药物研究进展[J].中国老年学杂志，2017，37（24）：6269-6272.
[16]	王雯，陈一丁，钱铁镛，等.沙格列汀联合二甲双胍对老年2型糖尿病患者血糖、血压及糖化血红蛋白的影响[J].中国老年学杂志，2016，36（2）：332-333.